Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging
- PMID: 22224404
- DOI: 10.1021/pr200784p
Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging
Abstract
In clinical diagnostics, it is of outmost importance to correctly identify the source of a metastatic tumor, especially if no apparent primary tumor is present. Tissue-based proteomics might allow correct tumor classification. As a result, we performed MALDI imaging to generate proteomic signatures for different tumors. These signatures were used to classify common cancer types. At first, a cohort comprised of tissue samples from six adenocarcinoma entities located at different organ sites (esophagus, breast, colon, liver, stomach, thyroid gland, n = 171) was classified using two algorithms for a training and test set. For the test set, Support Vector Machine and Random Forest yielded overall accuracies of 82.74 and 81.18%, respectively. Then, colon cancer liver metastasis samples (n = 19) were introduced into the classification. The liver metastasis samples could be discriminated with high accuracy from primary tumors of colon cancer and hepatocellular carcinoma. Additionally, colon cancer liver metastasis samples could be successfully classified by using colon cancer primary tumor samples for the training of the classifier. These findings demonstrate that MALDI imaging-derived proteomic classifiers can discriminate between different tumor types at different organ sites and in the same site.
Similar articles
-
Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier.J Proteome Res. 2010 Dec 3;9(12):6317-22. doi: 10.1021/pr100573s. Epub 2010 Nov 8. J Proteome Res. 2010. PMID: 21058730
-
Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression.Int J Oncol. 2012 Jan;40(1):148-56. doi: 10.3892/ijo.2011.1186. Epub 2011 Sep 5. Int J Oncol. 2012. PMID: 21894432
-
Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.Cancer. 2008 Feb 1;112(3):544-51. doi: 10.1002/cncr.23204. Cancer. 2008. PMID: 18085639
-
Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging: a review.Anal Chim Acta. 2011 Mar 25;690(1):26-34. doi: 10.1016/j.aca.2011.01.044. Epub 2011 Mar 2. Anal Chim Acta. 2011. PMID: 21414433 Review.
-
Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients.Anticancer Res. 2006 Sep-Oct;26(5A):3293-300. Anticancer Res. 2006. PMID: 17094443 Review.
Cited by
-
Matrix-Assisted Laser Desorption/Ionisation Mass Spectrometry Imaging in the Study of Gastric Cancer: A Mini Review.Int J Mol Sci. 2017 Dec 1;18(12):2588. doi: 10.3390/ijms18122588. Int J Mol Sci. 2017. PMID: 29194417 Free PMC article. Review.
-
Evolution of the liver biopsy and its future.Transl Gastroenterol Hepatol. 2021 Apr 5;6:20. doi: 10.21037/tgh.2020.04.01. eCollection 2021. Transl Gastroenterol Hepatol. 2021. PMID: 33824924 Free PMC article. Review.
-
MALDI-TOF Mass Spectrometry Analysis and Human Post-Mortem Microbial Community: A Pilot Study.Int J Environ Res Public Health. 2022 Apr 5;19(7):4354. doi: 10.3390/ijerph19074354. Int J Environ Res Public Health. 2022. PMID: 35410034 Free PMC article.
-
MALDI-TOF MS as a Novel Tool for the Estimation of Postmortem Interval in Liver Tissue Samples.Sci Rep. 2017 Jul 7;7(1):4887. doi: 10.1038/s41598-017-05216-0. Sci Rep. 2017. PMID: 28687792 Free PMC article.
-
Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.Oncotarget. 2014 Apr 15;5(7):1942-54. doi: 10.18632/oncotarget.1879. Oncotarget. 2014. PMID: 24722433 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials